Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | XIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66 |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | epithelial ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, Luciferase reporter assay, other |
| Sample | EOC cell lines (CAOV3 and OVCAR3) |
| Expression Pattern | up-regulated |
| Function Description | Lentivirus-mediated XIST upregulation had significant anticancer effects in CAOV3 and OVCAR3 cells by suppressing cancer cell proliferation, invasion, increasing cisplatin chemosensitivity and inhibiting in vivo tumor growth. Hsa-miR-214-3p was confirmed to directly bind XIST, and inversely downregulated in XIST-upregulated EOC cells. In EOC cells with XIST upregulation, secondary lentiviral transduction successfully upregulated hsa-miR-214-3p expression. Subsequently, hsa-miR-214-3p upregulation functionally reversed the anticancer effects of XIST-upregulation in EOC. |
| Pubmed ID | 30207107 |
| Year | 2018 |
| Title | Upregulation of Long Non-Coding RNA XIST Has Anticancer Effects on Epithelial Ovarian Cancer Cells Through Inverse Downregulation of hsa-miR-214-3p |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for epithelial ovarian cancer | OMIM COSMIC |